Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trialJean Chastre, Tomas Hruby, Philippe Eggimann et al.|Critical Care|2022Cited by 93
Alterations in CNS Activity Induced by Botulinum Toxin Treatment in Spasmodic Dysphonia: An H<sub>2</sub><sup>15</sup>O PET StudyOmar Ali, Allen R. Braun, Michael Thomassen et al.|Journal of Speech Language and Hearing Research|2006Cited by 91
Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trialBruno François, Alain Lepape, Hasan S. Jafri et al.|The Lancet Infectious Diseases|2021Cited by 88
635. Efficacy, Pharmacokinetics (PK), and Safety Profile of MEDI3902, an Anti-<i>Pseudomonas aeruginosa</i> Bispecific Human Monoclonal Antibody in Mechanically Ventilated Intensive Care Unit Patients; Results of the Phase 2 EVADE Study Conducted by the Public-Private COMBACTE-MAGNET Consortium in the Innovative Medicines Initiative (IMI) ProgramJean Chastre, Hasan S. Jafri, Bruno François et al.|Open Forum Infectious Diseases|2020Cited by 16
Performance of the Cepheid Methicillin-Resistant Staphylococcus aureus/S. aureus Skin and Soft Tissue Infection PCR Assay on Respiratory Samples from Mechanically Ventilated Patients for S. aureus Screening during the Phase 2 Double-Blind SAATELLITE StudyAlexey Ruzin, Mark T. Esser, Olivier Barraud et al.|Journal of Clinical Microbiology|2022Cited by 11